Liposarcoma Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

(Albany, USA) DelveInsight's, "Liposarcoma Pipeline Insight 2025," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Liposarcoma pipeline landscape. It covers the Liposarcoma pipeline drug profiles, including Liposarcoma clinical trials and nonclinical stage products. It also covers the Liposarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Liposarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Liposarcoma clinical trials studies, Liposarcoma NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key takeaways from the Liposarcoma Pipeline Report
• Over 15+ Liposarcoma companies are evaluating 15+ Liposarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Liposarcoma market would significantly increase market revenue.
• In March 2025, an open-label, non-randomized, multicenter trial enrolled patients with locally advanced or metastatic soft tissue sarcoma who had experienced disease progression within six months prior to enrollment.
• In March 2025, Ascentage Pharma Group Inc announced results of a Phase Ib/II Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors
• In March 2025, Boehringer Ingelheim announced results of Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma
• In January 2025, Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.
• The leading Liposarcoma Companies includes Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, and others.
• Promising Liposarcoma Pipeline Therapies includes Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and others.
• The Liposarcoma Companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The Liposarcoma pipeline therapies under development are focused on novel approaches to treat/improve Liposarcoma.

Request a sample and discover the recent breakthroughs happening in the Liposarcoma Pipeline landscape @ Liposarcoma Pipeline Outlook Report - https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Liposarcoma Overview
Liposarcoma is a rare type of soft tissue sarcoma that originates in fat cells, typically occurring in the deep soft tissues of the limbs, retroperitoneum, or abdomen. It is one of the most common soft tissue sarcomas in adults, often diagnosed between the ages of 40 and 60. The disease is classified into four major subtypes: well-differentiated, dedifferentiated, myxoid/round cell, and pleomorphic, each with distinct clinical behaviors and treatment responses.
The exact cause of liposarcoma remains unclear, but genetic mutations and chromosomal abnormalities are believed to play a significant role. Patients may experience symptoms such as painless swelling or a growing mass, though tumors in the retroperitoneum may remain asymptomatic until they reach an advanced stage, causing complications due to compression of nearby organs.
Treatment typically involves surgical resection, which is the primary approach for localized disease. Radiation therapy and chemotherapy are used in cases of high-grade or unresectable tumors, with emerging targeted therapies and immunotherapies being explored. Despite advances in treatment, recurrence and metastasis remain challenges, particularly in aggressive subtypes. Ongoing research into novel therapies, including tyrosine kinase inhibitors and immune checkpoint inhibitors, is crucial for improving patient outcomes.

Liposarcoma Emerging Drugs Profile
RAIN-32: Rain Therapeutics
RAIN-32 (milademetan) is a small molecule based oral inhibitor of mouse double minute 2 (MDM2). MDM2 is a critical regulator of tumor protein 53 (p53), which is known as the "guardian of the genome". RAIN-32 is in Phase III clinical studies for the treatment of Liposarcoma.

Selinexor: Karyopharm Therapeutics
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. The molecule functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, with the brand name XPOVIO, has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is in Phase III clinical studies for the treatment of Liposarcoma.

For further information, refer to the detailed Liposarcoma Drugs Launch, Liposarcoma Developmental Activities, and Liposarcoma News, click here for Liposarcoma Ongoing Clinical Trial Analysis -https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Liposarcoma Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Rain Therapeutics.

Liposarcoma Pipeline Segmentation
Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Types
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Find out more about the Liposarcoma Pipeline Segmentation, Therapeutics Assessment, Liposarcoma Emerging Drugs @ Liposarcoma Treatment Landscape - https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Liposarcoma Pipeline Report
• Coverage- Global
• Liposarcoma Companies- Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, and others.
• Liposarcoma Pipeline Therapies includes Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and others.
• Liposarcoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Liposarcoma Pipeline Companies and Therapies, click here @ Liposarcoma Unmet Needs and Analyst Views - https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Liposarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liposarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. RAIN-32: Rain Therapeutics
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Cabazitaxel: Sanofi
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. Ribociclib: Novartis Oncology
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. SDV-1101: Syndivia
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Liposarcoma Key Companies
21. Liposarcoma Key Products
22. Liposarcoma- Unmet Needs
23. Liposarcoma- Market Drivers and Barriers
24. Liposarcoma- Future Perspectives and Conclusion
25. Liposarcoma Analyst Views
26. Appendix

Got Queries? Find out the related information on Liposarcoma Mergers and acquisitions, Liposarcoma Licensing Activities @ Liposarcoma Recent Trends, and Future Perspectives - https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Healthcare Consulting: https://www.delveinsight.com/consulting
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast
• Aesthetic Implants Market: https://www.delveinsight.com/blog/aesthetic-implants-market-outlook-and-key-trends
• Competitive Intelligence Pharma: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/infographics/acute-on-chronic-liver-failure-aclf-market
• Acute Pancreatitis Market: https://www.delveinsight.com/infographics/acute-pancreatitis-market
• Chronic Hepatitis Delta Virus Market: https://www.delveinsight.com/infographics/hepatitis-d-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Acromegaly Market: https://www.delveinsight.com/report-store/acromegaly-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Adrenal Cortex Neoplasms Market: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.